Effects of two novel dopaminergic drugs, CV 205-502 and CQP 201-403, on prolactin and growth hormone secretion by human pituitary tumours in vitro.
Two novel dopaminergic drugs, designated CV 205-502 and CQP 201-403 have recently been developed by Sandoz Pharmaceuticals Ltd (Basle, Switzerland). The effects of these drugs on PRL and GH secretion by normal rat and tumorous human pituitary cells in vitro have been investigated. Low doses of both CV 205-502 and CQP 201-403 immediately and profoundly suppressed PRL secretion, which failed to recover up to 7 h after removal of the drugs. Similarly, CQP 201-403 significantly suppressed basal GH secretion by human pituitary somatotropic tumours in culture, and both drugs significantly reduced the stimulatory effect of GHRH. These effects are more potent and longer acting than the previously described in vitro effects of bromocriptine. It is concluded that CV 205-502 and CQP 201-403 hold potential for the treatment of patients with hyperprolactinaemia and, possibly, also in patients with acromegaly.
Venetikou
M S
MS
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Burrin
J M
JM
Woods
C A
CA
Yeo
T H
TH
Brownell
J
J
Adams
E F
EF
D000634:Aminoquinolines / Q000494:pharmacology*; D000818:Animals; D004873:Ergolines / Q000494:pharmacology*; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D010903:Pituitary Gland, Anterior / Q000187:drug effects; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D011388:Prolactin / Q000378:metabolism*; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects; D014407:Tumor Cells, Cultured
D000634:Aminoquinolines; D004873:Ergolines; D011954:Receptors, Dopamine; C049850:CQP 201-403; C046650:quinagolide; D011388:Prolactin; D013006:Growth Hormone